Should I buy or sell Astria Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATXS shares. View ATXS analyst ratings or view top-rated stocks .

What is Astria Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 12-month price objectives for Astria Therapeutics' shares. Their ATXS share price targets range from $17.00 to $27.00. On average, they anticipate the company's share price to reach $21.75 in the next year. This suggests a possible upside of 123.1% from the stock's current price. View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts .

How have ATXS shares performed in 2024?

Astria Therapeutics' stock was trading at $7.68 at the beginning of the year. Since then, ATXS shares have increased by 27.0% and is now trading at $9.75. View the best growth stocks for 2024 here .

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ATXS earnings forecast .

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its quarterly earnings data on Monday, March, 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.08.

When did Astria Therapeutics' stock split?

Astria Therapeutics shares reverse split on the morning of Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATXS

Astria Therapeutics (ATXS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ATXS Stock Alerts

$9.75

-0.79 (-7.50%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.48
▼
$10.64
50-Day Range: $9.75
▼
$16.69
52-Week Range: $4.26
▼
$16.90

Volume: 1.24 million shs
Average Volume: 1.02 million shs
Market Capitalization: $535.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.75

Get Astria Therapeutics alerts:

Astria Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 123.1% Upside
$21.75 Price Target
Short Interest: Bearish
11.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.55) to ($1.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

Medical Sector

676th out of 911 stocks

Pharmaceutical Preparations Industry

304th out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
Astria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Astria Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.37% of the float of Astria Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Astria Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Astria Therapeutics has recently increased by 151.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Astria Therapeutics does not currently pay a dividend.
Dividend Growth
Astria Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATXS.

2.0

News and Social Media Coverage

News Sentiment
Astria Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Astria Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for ATXS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
6 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Astria Therapeutics insiders have bought 26,830.52% more of their company's stock than they have sold. Specifically, they have bought $29,999,522.00 in company stock and sold $111,396.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Astria Therapeutics is held by insiders.
Percentage Held by Institutions
98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.55) to ($1.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Astria Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Astria Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Astria Therapeutics has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Astria Therapeutics Stock (NASDAQ:ATXS)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

ATXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATXS Stock News Headlines

April 11, 2024 | americanbankingnews.com

Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average of $14.02

April 9, 2024 | businesswire.com

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

April 3, 2024 | finance.yahoo.com

Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)

March 26, 2024 | markets.businessinsider.com

Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results

March 25, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)

March 25, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market Potential

March 25, 2024 | markets.businessinsider.com

Astria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial - Quick Facts

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

March 25, 2024 | finance.yahoo.com

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

March 23, 2024 | finance.yahoo.com

Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company

March 15, 2024 | finance.yahoo.com

ATXS Apr 2024 2.500 put

March 5, 2024 | businesswire.com

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Astria Therapeutics (ATXS)

March 5, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Astria Therapeutics (ATXS)

March 4, 2024 | businesswire.com

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

February 27, 2024 | finance.yahoo.com

ATXS Oct 2024 22.500 call

February 20, 2024 | finance.yahoo.com

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

February 20, 2024 | businesswire.com

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

February 17, 2024 | finance.yahoo.com

ATXS Mar 2024 22.500 call

February 17, 2024 | finance.yahoo.com

ATXS Mar 2024 12.500 call

February 6, 2024 | finance.yahoo.com

Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 1, 2024 | msn.com

Astria Therapeutics Announces Offering to Fund Future Operations

January 30, 2024 | finance.yahoo.com

Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc

January 30, 2024 | finance.yahoo.com

Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering

December 16, 2023 | msn.com

Astria Therapeutics files $500M mixed securities shelf

November 27, 2023 | finance.yahoo.com

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress

See More Headlines

Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATXS
CUSIP: N/A
CIK: 1454789
Web: www.catabasis.com
Phone: (617) 349-1971
Fax: 617-273-2637
Employees: 59
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $21.75
High Stock Price Target: $27.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +123.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.65%
Return on Assets: -33.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.73
Quick Ratio: 21.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.33 per share
Price / Book: 2.93

Miscellaneous

Outstanding Shares: 54,900,000
Free Float: 53,036,000
Market Cap: $535.28 million
Optionable: Optionable
Beta: 0.69

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Jill C. Milne Ph.D. (Age 56)
Co-Founder, CEO, President & Director
Comp: $928.52k
Mr. Benjamin S. Harshbarger J.D. (Age 55)
Chief Legal Officer
Comp: $621.91k
Mr. Noah C. Clauser CPA (Age 50)
CFO & Treasurer
Comp: $508.79k
Ms. Keri McGrail
Senior Vice President of Human Resources
Ms. Andrea L. Matthews
Chief Business Officer
Mr. Andrew A. Komjathy (Age 60)
Chief Commercial Officer
Dr. Christopher J. Morabito M.D. (Age 53)
Chief Medical Officer
Mr. John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings or view top-rated stocks.
What is Astria Therapeutics' stock price target for 2024?: 4 Wall Street analysts have issued 12-month price objectives for Astria Therapeutics' shares. Their ATXS share price targets range from $17.00 to $27.00. On average, they anticipate the company's share price to reach $21.75 in the next year. This suggests a possible upside of 123.1% from the stock's current price.
View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts.
How have ATXS shares performed in 2024?: Astria Therapeutics' stock was trading at $7.68 at the beginning of the year. Since then, ATXS shares have increased by 27.0% and is now trading at $9.75.
View the best growth stocks for 2024 here.
When is Astria Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATXS earnings forecast.

How were Astria Therapeutics' earnings last quarter?: Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its quarterly earnings data on Monday, March, 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.08.
When did Astria Therapeutics' stock split?: Astria Therapeutics shares reverse split on the morning of Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
How do I buy shares of Astria Therapeutics?: Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATXS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Astria Therapeutics (ATXS) Stock Price, News & Analysis

Astria Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Astria Therapeutics Stock (NASDAQ:ATXS)

ATXS Stock Price History

ATXS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ATXS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™